Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia
Journal article published in 2010 by
Francesco Buccisano,
Luca Maurillo,
Mi Del Principe,
Alessandra Spagnoli 
,
Mi Consalvo,
Daniela Fraboni,
Paola Panetta,
Tiziana Ottone,
E. Ammatuna,
Df Angelini,
Serena Lavorgna,
A. Venditti,
A. Diamantini,
Pietro Bulian,
S. Campagna
and other authors.
,
Mi Consalvo,
Daniela Fraboni,
Paola Panetta,
Tiziana Ottone,
E. Ammatuna,
Df Angelini,
Serena Lavorgna,
A. Venditti,
A. Diamantini,
Pietro Bulian,
S. Campagna
and other authors.
Abstract
A total of 143 adult acute myeloid leukemia (AML) patients with available karyotype (K) and FLT3 gene mutational status were assessed for minimal residual disease (MRD) by flow cytometry. Twenty-two (16%) patients had favorable, 115 (80%) intermediate, and 6 (4%) poor risk K; 19 of 129 (15%) carried FLT3-ITD mutation. Considering postconsolidation MRD status, patients with good/intermediate-risk K who were MRD(-) had 4-year relapse-free survival (RFS) of 70% and 63%, and overall survival (OS) of 84% and 67%, respectively. Patients with good- and intermediate-risk K who were MRD(+) had 4-year RFS of 15% and 17%, and OS of 38% and 23%, respectively (P